| Identification | More | [Name]
Cefozopran | [CAS]
113359-04-9 | [Synonyms]
CEFOZOPRAN
sce2787
Cefozopran hydrochloride
1-[[(6R,7R)-7-[[2Z)-(5-Amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]imidazo[1,2-b]pyridazinium Inner Salt
Firstci
SCE-1787
1-[[(6R,7R)-7-[[(2Z)-(5-Amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-imidazo[1,2-b]pyridazinium hydroxide inner salt
Firstcin)
SCE-2787：Fastocin | [EINECS(EC#)]
601-249-3 | [Molecular Formula]
C19H17N9O5S2 | [MDL Number]
MFCD00883679 | [Molecular Weight]
515.53 | [MOL File]
113359-04-9.mol |
| Chemical Properties | Back Directory | [Appearance]
White To Pale-Yellow Powder | [Melting point ]
>300°C | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [Usage]
Antibacterial | [InChIKey]
QDUIJCOKQCCXQY-RWDKEWRNNA-N | [SMILES]
C(C1=C(CS[C@]2([H])[C@H](NC(=O)/C(/C3N=C(N)SN=3)=N\OC)C(=O)N12)C[N+]1C=CN2N=CC=CC=12)(=O)[O-] |&1:5,7,r| | [CAS DataBase Reference]
113359-04-9(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Chemical Properties]
White To Pale-Yellow Powder | [Uses]
Antibacterial | [Definition]
ChEBI: Cefozopran is a fourth-generation cephalosporin antibiotic having imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively. It is a cephalosporin, a member of thiadiazoles and an imidazopyridazine. | [Antimicrobial activity]
An aminothiazole cephalosporin formulated as the hydrochloride.
Activity is similar to that of ceftazidime, but it is more
active against methicillin-susceptible staphylococci (MIC 1
mg/L). Representative MICs against Gram-negative species
are: Esch coli 0.25 mg/L; K. pneumoniae 1 mg/L; Ps. aeruginosa
1–8 mg/L. Activity against Acinetobacter spp., Sten. maltophilia
and B. fragilis group is poor.
A 20-min infusion of 1.5 g achieved a plasma concentration
of around 125 mg/L at the end of infusion. Almost 90%
of the dose was excreted in the urine over 24 h. The mean terminal
half-life was around 2 h. Adverse reactions appear to be
typical of those of other group 6 cephalosporins.
It is available in Japan. | [in vivo]
Cefozopran (SCE-2787) (5-80 mg/kg; s.c.; twice a day for 5 days; four-week-old ICR male mice) is effective against acute respiratory tract infections caused by Kiebsiella pneumonia DT-S. In the model of chronic respiratory tract infection caused by K. pneumoniae 27, Cefozopran (20-80 mg/kg; s.c.; twice a day for 7 days; five-week-old CBA/J female mice) is as effective as Ceftazidime[2]. | [IC 50]
β-lactam | [storage]
Store at -20°C |
|
|